Table 2.
Overall incidence of hepatic failure, renal failure, respiratory failure, and heart failure (per 1,000 person-years) and estimated HRs in ACO patients taking statins compared with ACO patients without statins using a time-dependent regression model.
| Statin | ||
|---|---|---|
| Variables | No (N = 7,443) | Yes (N = 1,211) |
| Hepatic failure | ||
| Person-years | 42822 | 9519 |
| Follow-up time (y), mean ± SD | 5.75 ± 3.45 | 7.86 ± 2.94 |
| Event, n | 694 | 82 |
| Rate | 16.2 | 8.61 |
| cHR (95% CI) | 1 (reference) | 0.58 (0.46, 0.72)*** |
| aHR (95% CI) a | 1 (reference) | 0.50 (0.40, 0.64)*** |
| Renal failure | ||
| Person-years | 45,034 | 9,684 |
| Follow-up time (y), mean ± SD | 6.05 ± 3.45 | 8.00 ± 3.41 |
| Event, n | 510 | 74 |
| Rate | 11.3 | 7.64 |
| cHR (95% CI) | 1 (reference) | 0.68 (0.53, 0.87)** |
| aHR (95% CI) a | 1 (reference) | 0.49 (0.38, 0.64)*** |
| Respiratory failure | ||
| Person-years | 46,898 | 9,897 |
| Follow-up time (y), mean ± SD | 6.30 ± 3.42 | 8.17 ± 2.78 |
| Event, n | 20 | 3 |
| Rate | 0.43 | 0.30 |
| cHR (95% CI) | 1 (reference) | 0.68 (0.20, 2.30) |
| aHR (95% CI) a | 1 (reference) | 0.61 (0.17, 2.21) |
| Heart failure | ||
| Person-years | 43,215 | 9,461 |
| Follow-up time (y), mean±SD | 5.81 ± 3.50 | 7.96 ± 2.88 |
| Event, n | 835 | 77 |
| Rate | 19.3 | 7.99 |
| cHR (95% CI) | 1 (reference) | 0.44 (0.35, 0.56)*** |
| aHR (95% CI) a | 1 (reference) | 0.47 (0.37, 0.60)*** |
a
Adjusted for age; sex; comorbidity of sleep disorder, diabetes, hypertension, hyperlipidemia, CAD, stroke, hepatitis B, and hepatitis C; and ICS and OS.
cHR, crude hazard ratio; aHR, adjusted hazard ratio; ICS, inhaled corticosteroid; OS, oral steroid.
**P < 0.01, ***P < 0.001.